Annet G H Roodvoets
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annet G H Roodvoets has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Hein Putter
Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands
5 shared publications - Elma Meershoek-Klein Kranenbarg
Department of Surgery, Leiden University Medical Center, Leiden, South Holland, The Netherlands
4 shared publications - Wilma. E. Mesker
Leiden University Medical Center
4 shared publications - Gabi W. van Pelt
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
3 shared publications - Johan Hjm van Krieken
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publications - Rob A. E. M. Tollenaar
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 4 April 2025
- Published by Wiley in Histopathology
- Vol. 87 (1) , 44-57
The tumour–stroma ratio as predictive aid towards a biopsy‐based treatment strategy in rectal carcinoma
Aims: Tumour–stroma ratio (TSR) scores of biopsy material in rectal carcinoma (RC) could aid a biomarker‐based, upfront and personalised treatment strategy selection for RC patients. In a large retrospective, multicentre cohort, we aimed to validate the predictive value of biopsy‐scored TSR on neoadjuvant therapy response, and secondarily, disease‐free and overall survival (DFS, OS).Methods and results: Scanned haematoxylin and eosin‐stained RC biopsy slides were collected from Leiden University Medical Center (N = 116) and from the clinical PROCTOR‐SCRIPT (N = 142) and RAPIDO (N = 271) trials. TSR was scored per protocol and categorised as stroma‐low (≤ 50%) or stroma‐high (> 50%). Major response was defined as tumour regression grade (TRG) 1 + 2 by Mandard, including pathological complete response. Ultimately, a large and varied cohort with 373 RC patients was established. Locally advanced RC was more often stroma‐high (P < 0.001). We subsequently observed significantly lower major response rates in the stroma‐high RC after a neoadjuvant treatment approach (hazard ratio = 0.63, 95% confidence interval = 0.41–0.99; P = 0.044). Despite correction for well‐known risk factors in Cox hazard regression analysis, such as (y)pTNM substages or residual tumour status, the TSR had no singular significant influence on DFS nor OS in multivariate analysis (P = 0.438; P = 0.934, respectively).Conclusions: Biopsy‐scored TSR can predict neoadjuvant therapy efficacy, as RC patients with stroma‐high biopsies show less major response. However, patient survival is multifactorial, although response is an important predictor, influenced by TSR. Scoring TSR on RC biopsy material is a reliable histological parameter, implementation of which in treatment guidelines could improve upfront selection for a watch‐and‐wait strategy.
- 4 April 2025
- Published by Wiley in Histopathology
- Vol. 87 (1) , 44-57
Open AccessThe tumour–stroma ratio as predictive aid towards a biopsy‐based treatment strategy in rectal carcinoma
Aims: Tumour–stroma ratio (TSR) scores of biopsy material in rectal carcinoma (RC) could aid a biomarker‐based, upfront and personalised treatment strategy selection for RC patients. In a large retrospective, multicentre cohort, we aimed to validate the predictive value of biopsy‐scored TSR on neoadjuvant therapy response, and secondarily, disease‐free and overall survival (DFS, OS).Methods and results: Scanned haematoxylin and eosin‐stained RC biopsy slides were collected from Leiden University Medical Center (N = 116) and from the clinical PROCTOR‐SCRIPT (N = 142) and RAPIDO (N = 271) trials. TSR was scored per protocol and categorised as stroma‐low (≤ 50%) or stroma‐high (> 50%). Major response was defined as tumour regression grade (TRG) 1 + 2 by Mandard, including pathological complete response. Ultimately, a large and varied cohort with 373 RC patients was established. Locally advanced RC was more often stroma‐high (P < 0.001). We subsequently observed significantly lower major response rates in the stroma‐high RC after a neoadjuvant treatment approach (hazard ratio = 0.63, 95% confidence interval = 0.41–0.99; P = 0.044). Despite correction for well‐known risk factors in Cox hazard regression analysis, such as (y)pTNM substages or residual tumour status, the TSR had no singular significant influence on DFS nor OS in multivariate analysis (P = 0.438; P = 0.934, respectively).Conclusions: Biopsy‐scored TSR can predict neoadjuvant therapy efficacy, as RC patients with stroma‐high biopsies show less major response. However, patient survival is multifactorial, although response is an important predictor, influenced by TSR. Scoring TSR on RC biopsy material is a reliable histological parameter, implementation of which in treatment guidelines could improve upfront selection for a watch‐and‐wait strategy.
- Top Cited PapersOpen Access
- 20 January 2023
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 278 (4) , e766-e772
Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery
Objective: To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. Background: Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3 years, LRF rate was comparable between TNT and chemoradiotherapy in the RAPIDO trial. Methods: A total of 920 patients were randomized between an experimental (EXP, short-course radiotherapy, chemotherapy, and surgery) and a standard-care group (STD, chemoradiotherapy, surgery, and optional postoperative chemotherapy). LRFs, including early LRF (no resection except for organ preservation/R2 resection) and locoregional recurrence (LRR) after an R0/R1 resection, were analyzed. Results: Totally, 460 EXP and 446 STD patients were eligible. At 5.6 years (median follow-up), LRF was detected in 54/460 (12%) and 36/446 (8%) patients in the EXP and STD groups, respectively (P=0.07), in which EXP patients were more often treated with 3-dimensional-conformed radiotherapy (P=0.029). In the EXP group, LRR was detected more often [44/431 (10%) vs. 26/428 (6%); P=0.027], with more often a breached mesorectum (9/44 (21%) vs. 1/26 (4); P=0.048). The EXP treatment, enlarged lateral lymph nodes, positive circumferential resection margin, tumor deposits, and node positivity at pathology were the significant predictors for developing LRR. Location of the LRRs was similar between groups. Overall survival after LRF was comparable [hazard ratio: 0.76 (95% CI, 0.46–1.26); P=0.29]. Conclusions: The EXP treatment was associated with an increased risk of LRR, whereas the reduction in disease-related treatment failure and distant metastases remained after 5 years. Further refinement of the TNT in rectal cancer is mandated.
- 20 January 2023
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 278 (4) , e766-e772
Top Cited PapersOpen AccessLocoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery
Objective: To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. Background: Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3 years, LRF rate was comparable between TNT and chemoradiotherapy in the RAPIDO trial. Methods: A total of 920 patients were randomized between an experimental (EXP, short-course radiotherapy, chemotherapy, and surgery) and a standard-care group (STD, chemoradiotherapy, surgery, and optional postoperative chemotherapy). LRFs, including early LRF (no resection except for organ preservation/R2 resection) and locoregional recurrence (LRR) after an R0/R1 resection, were analyzed. Results: Totally, 460 EXP and 446 STD patients were eligible. At 5.6 years (median follow-up), LRF was detected in 54/460 (12%) and 36/446 (8%) patients in the EXP and STD groups, respectively (P=0.07), in which EXP patients were more often treated with 3-dimensional-conformed radiotherapy (P=0.029). In the EXP group, LRR was detected more often [44/431 (10%) vs. 26/428 (6%); P=0.027], with more often a breached mesorectum (9/44 (21%) vs. 1/26 (4); P=0.048). The EXP treatment, enlarged lateral lymph nodes, positive circumferential resection margin, tumor deposits, and node positivity at pathology were the significant predictors for developing LRR. Location of the LRRs was similar between groups. Overall survival after LRF was comparable [hazard ratio: 0.76 (95% CI, 0.46–1.26); P=0.29]. Conclusions: The EXP treatment was associated with an increased risk of LRR, whereas the reduction in disease-related treatment failure and distant metastases remained after 5 years. Further refinement of the TNT in rectal cancer is mandated.
- Top Cited Papers
- 1 June 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 147, 75-83
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial
- 1 June 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 147, 75-83
Top Cited PapersCompliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial
- Open Access
- 14 June 2019
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 8 (6) , e13464
Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Colon cancer treatment is dependent on stage at diagnosis. The current TNM (Tumour-Node-Metastasis) staging for the selection of patients for adjuvant chemotherapy needs additional prognostic and predictive biomarkers. Better decision-making for chemotherapy will result in reducing over- and under-treatment. We developed a new, easy to apply, practice-changing method to select colon cancer patients for adjuvant (chemo)therapy: the tumour-stroma ratio (TSR). The TSR distinguishes within stage II-III patients who will likely benefit of adjuvant (chemo)therapy and from those who will not. Objective: The study goal is to add the TSR to current routine pathology evaluation in addition to the TNM classification. Pathologists will be instructed for scoring the TSR in combination with a quality assessment program. An international multicentre study will validate the parameter prospectively. Methods: The study prepares for implementation of the TSR to current TNM guidelines, using routinely Haematoxylin and Eosin stained tumour tissue sections. Part 1. An E-learning module with a quality assessment program in the framework of the European Society of Pathology will be developed. This module will be used to assess the reliability and reproducibility of TSR, conducted by national and international pathologists. Part 2. Validation of the TSR in a prospective cohort of colon cancer pathological stage II-III patients in a multicentre setting. In total 1500 patients will be included. Results: The results of part 1 will be expected first half of 2019. For part 2, the inclusion was started end 2018 and will take 3 years, with an additional follow-up of 3 years. Conclusions: The main endpoints of this study are: Part 1. Instructed (international) pathologists who are able to reliably score TSR, resulting in low intra- and inter-observer variation. Part 2. Confirmation of significant survival differences for patients with a stroma-high tumour versus patients with a stroma-low tumour. Based on these findings modification in current treatment guidelines will be suggested. Clinical Trial: The Netherlands Trial Registry (NTR 7270). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=7270
- 14 June 2019
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 8 (6) , e13464
Open AccessUniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Colon cancer treatment is dependent on stage at diagnosis. The current TNM (Tumour-Node-Metastasis) staging for the selection of patients for adjuvant chemotherapy needs additional prognostic and predictive biomarkers. Better decision-making for chemotherapy will result in reducing over- and under-treatment. We developed a new, easy to apply, practice-changing method to select colon cancer patients for adjuvant (chemo)therapy: the tumour-stroma ratio (TSR). The TSR distinguishes within stage II-III patients who will likely benefit of adjuvant (chemo)therapy and from those who will not. Objective: The study goal is to add the TSR to current routine pathology evaluation in addition to the TNM classification. Pathologists will be instructed for scoring the TSR in combination with a quality assessment program. An international multicentre study will validate the parameter prospectively. Methods: The study prepares for implementation of the TSR to current TNM guidelines, using routinely Haematoxylin and Eosin stained tumour tissue sections. Part 1. An E-learning module with a quality assessment program in the framework of the European Society of Pathology will be developed. This module will be used to assess the reliability and reproducibility of TSR, conducted by national and international pathologists. Part 2. Validation of the TSR in a prospective cohort of colon cancer pathological stage II-III patients in a multicentre setting. In total 1500 patients will be included. Results: The results of part 1 will be expected first half of 2019. For part 2, the inclusion was started end 2018 and will take 3 years, with an additional follow-up of 3 years. Conclusions: The main endpoints of this study are: Part 1. Instructed (international) pathologists who are able to reliably score TSR, resulting in low intra- and inter-observer variation. Part 2. Confirmation of significant survival differences for patients with a stroma-high tumour versus patients with a stroma-low tumour. Based on these findings modification in current treatment guidelines will be suggested. Clinical Trial: The Netherlands Trial Registry (NTR 7270). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=7270
- Open Access
- 23 January 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study (Preprint)
BACKGROUND Colon cancer treatment is dependent on the stage at diagnosis. The current Tumor-Node-Metastasis (TNM) staging for the selection of patients for adjuvant chemotherapy needs additional prognostic and predictive biomarkers. Better decision making for chemotherapy will result in reducing over- and undertreatment. We developed a new, easy-to-apply, practice-changing method to select colon cancer patients for adjuvant chemotherapy: the tumor-stroma ratio (TSR). The TSR distinguishes within stage II-III patients who will likely benefit from adjuvant chemotherapy and those who will not. OBJECTIVE The aim of the study was to add, in addition to the TNM classification, the TSR to current routine pathology evaluation. Pathologists will be instructed for scoring the TSR in combination with a quality assessment program. An international multicenter study will validate the parameter prospectively. METHODS The study is designed for future implementation of the TSR to the current TNM guidelines, using routinely Haematoxylin- and Eosin-stained tumor tissue sections. In part 1 of the study, an electronic learning (e-learning) module with a quality assessment program using the European Society of Pathology framework will be developed. This module will be used to assess the reliability and reproducibility of the TSR, conducted by national and international pathologists. Part 2 will involve the validation of the TSR in a prospective cohort of colon cancer p-stage II-III patients in a multicenter setting. In total, 1500 patients will be included. RESULTS The results of part 1 will be expected in the first half of 2019. For part 2, the inclusion of patients in the prospective study, which started at the end of 2018, will take 3 years with an additional follow-up after another 3 years. CONCLUSIONS The main endpoints of this study are as follows: in part 1, trained (international) pathologists who are able to reliably score the TSR, resulting in low intra- and interobserver variation; in part 2, confirmation of significant survival differences for patients with a stroma-high tumor versus patients with a stroma-low tumor. On the basis of these findings, a modification in current treatment guidelines will be suggested. CLINICALTRIAL Netherlands Trial Register NTR7270; https://www.trialregister.nl/trial/7072 INTERNATIONAL REGISTERED REPOR DERR1-10.2196/13464
- 23 January 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessUniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study (Preprint)
BACKGROUND Colon cancer treatment is dependent on the stage at diagnosis. The current Tumor-Node-Metastasis (TNM) staging for the selection of patients for adjuvant chemotherapy needs additional prognostic and predictive biomarkers. Better decision making for chemotherapy will result in reducing over- and undertreatment. We developed a new, easy-to-apply, practice-changing method to select colon cancer patients for adjuvant chemotherapy: the tumor-stroma ratio (TSR). The TSR distinguishes within stage II-III patients who will likely benefit from adjuvant chemotherapy and those who will not. OBJECTIVE The aim of the study was to add, in addition to the TNM classification, the TSR to current routine pathology evaluation. Pathologists will be instructed for scoring the TSR in combination with a quality assessment program. An international multicenter study will validate the parameter prospectively. METHODS The study is designed for future implementation of the TSR to the current TNM guidelines, using routinely Haematoxylin- and Eosin-stained tumor tissue sections. In part 1 of the study, an electronic learning (e-learning) module with a quality assessment program using the European Society of Pathology framework will be developed. This module will be used to assess the reliability and reproducibility of the TSR, conducted by national and international pathologists. Part 2 will involve the validation of the TSR in a prospective cohort of colon cancer p-stage II-III patients in a multicenter setting. In total, 1500 patients will be included. RESULTS The results of part 1 will be expected in the first half of 2019. For part 2, the inclusion of patients in the prospective study, which started at the end of 2018, will take 3 years with an additional follow-up after another 3 years. CONCLUSIONS The main endpoints of this study are as follows: in part 1, trained (international) pathologists who are able to reliably score the TSR, resulting in low intra- and interobserver variation; in part 2, confirmation of significant survival differences for patients with a stroma-high tumor versus patients with a stroma-low tumor. On the basis of these findings, a modification in current treatment guidelines will be suggested. CLINICALTRIAL Netherlands Trial Register NTR7270; https://www.trialregister.nl/trial/7072 INTERNATIONAL REGISTERED REPOR DERR1-10.2196/13464